{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_codes_code in Code Literal (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2019)
Source URL:
First approved in 2019
Source:
21 CFR 333E
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2003)
First approved in 1987
Source:
PROLASTIN-C by GRIFOLS THERAPEUTICS LLC
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02614833: Phase 2 Interventional Completed Adenocarcinoma Breast Stage IV
(2015)
Source URL:
Class:
PROTEIN
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
